Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : YEEHAW CANDIDATES -- Ignore unavailable to you. Want to Upgrade?

To: Ken W who wrote (1659)	4/7/2003 11:44:40 PM
From: Jibacoa	Respond to of 23958

Ken, IDEV gave a buy signal on March 28 when the S average crossed above the M and the averages got on the right sequence. <g> (The data at that time was P=2.40 S=2.35 M=2.33 & L=2.21) This was confirmed on April 1 when the stock started to move up with increasing volume of 458K and it finished at the H for the day. The up-move continued for the next 2 days with the volume on April 2 up to 930K. On April 3 when it closed above its December 9 H the volume was still 409K Now you have to watch it closely for a possible toping pattern. (Today's C of 2.98 was above Friday's C of 2.85 but the H at 3.15 was below Friday's H of 3.18 as the volume came down to 190.57K ) The averages remain on the right sequence and the Price hasn't dipped below the S average.(The data today: P=2.98 S=2.83 M=2.60 L=2.33) I would continue to hold as long as the P stays above the S average. That seems to be the first support level.<g>(The next are at 2.75 and at the M average, presently at 2.60) From a F perspective, it is on their favor the scheduled AUA meeting starting on April 26 when they will be presenting the results of the recently completed PIII with trospium. If the stock can get to close some more of its June 7 down-gap,which was made on a volume of 12.564M when PFE elected not to pursue further development of pagoclone (G=5.52 to 1.75)it could have some further up-move. (AVE also declined to get involved on development of pagoclone.) On their deal with Shire for long acting trospium, IDEV will be responsible for all development costs and the commercialization of the product and their cash/share at $0.77 doesn't look very "solid".<g> As I have been writting this note, I have been watching the news about the bombing of Sadam's lunch meeting. Will see if they can confirm that they got him this time. RAGL Bernard